You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Revenues during the quarter were $716.3 million, beating Wall Street estimates, while full year 2019 revenues totaled $2.41 billion.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.
Waters posted revenues of $577.3 million, short of the average Wall Street estimate of $588.9 million, as soft US pharma sales negatively impacted businesses.
Though Meehan was cautious on Waters in the near term, he provided a favorable outlook on Thermo Fisher Scientific.
The Swiss company markets the WAVE system, a waveguide interferometry-based instrument for studying molecular interactions in real time.
More powerful and user-friendly mass spec systems could drive an uptick in interest in the technique, suggested a leading top-down researcher.
The company's Q2 revenues were up less than 1 percent from $596.2 million in Q2 2018, and short of the average Wall Street estimate of $601.4 million.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology.
New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.
According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.
The US National Institutes of Health has a new initiative to address structural racism in biomedical research.
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.